Inspired by the positive results that were obtained for some of the 68Ga- and 64Cu-labeled GRPR- and αvβ3-bispecific ligands, another attempt was recently made to further improve the in vivo pharmacokinetics and tumor uptakes of such agents by combining not only one c(RGDyK) peptide (cyclo(Arg-Gly-Asp-DTyr-Lys)) unit with a GRPR-binding one, but to include two αvβ3-affine peptide copies to obtain NODAGA- and DOTA-modified heterotrimers 19 and 20 [91] instead of heterodimers. The gene discussed is GRPR; the disease is neoplasm.